As of Friday close, Organon & Co.’s (NYSE:OGN) stock was down -$0.32, moving down -1.72 percent to $18.26. The average number of shares traded per day over the past five days has been 2,418,600 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.28 fall in that time frame. In the last twenty days, the average volume was 2,327,575, while in the previous 50 days, it was 2,223,020.
Since last month, OGN stock retreated -16.70%. Shares of the company fell to $18.22 on 09/22/23, the lowest level in the past month. A 52-week high of $32.43 was reached on 01/18/23 after having rallying from a 52-week low of $18.57. Since the beginning of this year, OGN’s stock price has dropped by -34.62% or -$9.67, and marked a new high 10 times. However, the stock has declined by -43.69% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Right now, Organon & Co. (OGN) has a P/E ratio of about 6.19. The stock’s beta is 0.83.
The latest dividend of $0.28 per share was paid out, remained unchanged from last year’s $0.28.
Financial Health
In the three months ended June 29, Organon & Co.’s quick ratio stood at 1.20, while its current ratio was 1.70, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 61.70% percent. In the year ended June 29, EBITDA margin amounted to 31.28%, whereas operating margins totaled 14.30%. Based on annual data, OGN earned $3.88 billion in gross profit and brought in $6.17 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 11.40%. Return on equity (ROE) for the past 12 months was -92.80%.
In Organon & Co.’s quarter-end financial report for June 29, it reported total debt of $8.72 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. OGN’s revenue rose 1.43% to $1.54 billion during the quarter, while net income inched up to $1.61 billion. While analysts expected Organon & Co. to report $1.01 quarterly earnings, the actual figure was $1.31 per share, beating the consensus estimate by 29.70%. During the quarter, the company generated $446.0 million in EBITDA. The liabilities of Organon & Co. were 11.53 billion at the end of its most recent quarter ended June 29, and its total debt was $8.73 billion. The value of shareholders’ equity is $255.57 million.
Technical Picture
This quick technical analysis looks at Organon & Co.’s (OGN) price momentum. With a historical volatility rate of 20.67%, the RSI 9-day stood at 21.06% on 22 September.
With respect to its five-day moving average, the current Organon & Co. price is down by -6.55% percent or -$1.28. At present, OGN shares trade -15.50% below its 20-day simple moving average and -25.47% percent below its 100-day simple moving average. However, the stock is currently trading approximately -11.83% below its SMA50 and -30.70% below its SMA200.
Stochastic coefficient K was 0.71% and Stochastic coefficient D was 1.59%, while ATR was 0.49. Given the Stochastic reading of 1.04% for the 14-day period, the RSI (14) reading has been calculated as 26.72%. As of today, the MACD Oscillator reading stands at -0.55, while the 14-day reading stands at -0.81.
Analyst Ratings
Barclays launched its rating on Organon & Co. (NYSE: OGN) to an Overweight in a note to investors on September 21, 2023. Organon & Co. (OGN) has been rated Overweight by analysts. According to 0 brokerage firms, OGN is a sell, and 3 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 2 analysts rate Organon & Co. stock as buy, with 3 recommending it as overweight.
With a median target price of $27.50, the current consensus forecast for the stock is $23.00 – $43.00. Based on these forecasts, analysts predict Organon & Co. (OGN) will achieve an average price target of $29.75.
